Souhaitez-vous accéder aux communiqués récents ?

Oslo (Norway), 13 July 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced a 6 month extension of the evaluation period under its preclinical research...

Oslo, 27 May 2020. The Annual General Meeting in PCI Biotech Holding ASA took place today, 27 May 2020. All proposals were resolved by the Annual General Meeting as presented in the notice convening...

Oslo, 26 May 2020. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall...

Oslo, Norway 6 May 2020 - The Annual General Meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 27 May 2020 at 10:00am (CEST). Due to...

Oslo (Norway), 6 May 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first quarter 2020 results. Please find enclosed the report and...

Oslo, Norway, 30 April 2020 - PCI Biotech announces the appointment of Mr Ludovic Robin, PharmD, MBA, as Chief Business Officer (CBO). Mr Robin will also serve as a member of PCI Biotech’s executive...

Oslo, Norway, 28 April 2020 - PCI Biotech’s Q1 2020 interim report will be released on 6 May, 2020 at 07.00 CEST. The interim report and presentation will be made available on www.newsweb.no and on...

Oslo, Norway, April 22, 2020. The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2019 and the report is attached. The Annual Report 2019 is also available on the...

Oslo, Norway, 31 March 2020 - PCI Biotech announces the appointment of Dr Amir Snapir, MD, PhD as Chief Medical Officer (CMO). Dr Snapir will also serve as a member of PCI Biotech’s executive...

Oslo (Norway), 26 March 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a...